513 results about "Target antigen" patented technology

An antigen-binding molecule that binds to a target antigen, comprising (i) a target antigen-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting measles virus nucleoprotein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 5E2 and 5G9 and can efficiently and specifically recognize measles virus nucleoprotein, amino acid sequences of complementary determining regions (CDR) of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting measles virus nucleoprotein. The risk of non-specific binding and cross reaction is obviously reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography, and provides a stable and reliable biological recognition tool for rapid and accurate detection of measles viruses.

The invention relates to a colorectal cancer treatment effect prediction system based on artificial intelligence and multiple immunohistochemistry, which comprises: (i) an analysis selection module for analyzing tumor tissues and selecting target cells and / or target antigens; (ii) a preparation module for preparing a colorectal cancer immunosuppressive unit (CCIM) image from the selected target antigen by using a multiplex immunohistochemical technique; and (iii) an identification module that predicts a therapeutic effect of colorectal cancer based on the CCIM image.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

The invention discloses a device and a method for designing a humanized antibody based on CDR transplantation, and a computer readable storage medium. The method comprises the following steps: replacing an antigen complementarity determining region sequence of a humanized antibody sequence with an antigen complementarity determining region sequence of a target antigen heterologous antibody to obtain a CDR region transplantation antibody; the method comprises the following steps: performing single amino acid reverse mutation on different amino acid sites of a CDR region transplantation antibody and a heterologous antibody, and comparing structural difference scores of protein three-dimensional structures before and after mutation; retaining the single amino acid reverse mutation site with the structural difference score less than or equal to 1, and finally obtaining the CDR transplanted humanized antibody of the target antigen. According to the method, the similarity of heterologous antibody and human antibody sequences can be increased, the immunogenicity of the target antigen human antibody is reduced, and the affinity is maintained.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The invention relates to the field of immunity, in particular to a T cell receptor with improved affinity, a nucleic acid molecule, a carrier, a cell and a medicine containing the T cell receptor, the nucleic acid molecule, the carrier and the cell for treating tumors. The T cell receptor includes a TCR [alpha] chain variable region and a TCR [beta] chain variable region, which have activity to bind to a KRAS G12V epitope and an HLA-A * 11 complex, and the TCR [alpha] chain variable region includes CDR1 [alpha], CDR2 [alpha] and CDR3 [alpha] complementarity determining regions, and the TCR [beta] chain variable region includes CDR1 [beta], CDR2 [beta] and CDR3 [beta] complementarity determining regions. The TCR provided by the invention has high-affinity target antigen peptide binding capacity, remarkably improves the target cell recognition capacity, shows good activation and killing activity, and shows high technical value and clinical application potential.

Genetically engineered immune cells, which express at least two metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered immune cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The invention belongs to the field of nano biomedicine, and particularly discloses a yeast bionic vaccine based on a metal organic framework ZIF-8 as well as a construction method and application of the yeast bionic vaccine, and the structure of the bionic vaccine is that ZIF-8 loaded with antigen OVA is encapsulated in a yeast shell. The invention relates to preparation and anti-tumor immune response of the bionic vaccine. The yeast shell is obtained by performing acid and alkali treatment and organic solvent washing on saccharomycetes and has the effects of targeting antigen presenting cells and stimulating immune response, and the antigen-loaded metal organic framework ZIF-8 is encapsulated in the yeast shell and has relatively good stability and an effect of continuously releasing antigens. The ZIF-8 is decomposed in antigen presenting cells, and lysosome escape of the antigen is induced. The yeast bionic vaccine provided by the invention can specifically target antigen presenting cells, continuously release tumor antigens in vivo, mediate escape of lysosome of the antigens and stimulate strong anti-tumor immune response, and has a better application prospect.

The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and / or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and / or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and / or T cell persistence).

To provide methods and compositions for use in treating cancer, which may be achieved by targeting of a tumor microenvironment.SOLUTION: The invention provides an immune cell engineered to express: (a) a chimeric antigen receptor (CAR) polypeptide including an extracellular domain including a first antigen-binding domain that binds to a first antigen and a second antigen-binding domain that binds to a second antigen; and (b) a bispecific T cell engager (BiTE), wherein the BiTE binds to a target antigen and a T cell antigen.SELECTED DRAWING: Figure 1

Provided are proteins capable of engaging NK cells in cancer therapy, especially multi-specific proteins capable of binding IL 15 receptor, NKp46, target antigen of interest, and optionally Fc gamma receptor such as CD16a. Also provided are NKp46-binding proteins. The proteins have utility in the treatment of diseases, such as cancer.

The present invention relates to multispecific constructs that specifically bind to IL- 13 and a second target antigen (e.g., TSLP, IL-17A, IL-17F, TNF-α, and IFN-γ). Also provided are antibody constructs that specifically bind to IL-13. Compositions, kits, methods of use (e.g., treating inflammatory disease), and methods of making thereof are also provided.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

The invention relates to agents and methods for targeted delivery of payloads to cells. The payload includes a variety of molecules such as therapeutic or diagnostic agents and, in particular, toxins, immunomodulators or radiodiagnostics. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and at least two tags (tag conjugate) and a compound binding to the tags of the tag conjugate and a target antigen, e.g., a cell surface antigen on a target cell, (docking compound).

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

Provided are a CAR library used to screen scFvs that can be functional in CAR-T cells, and an scFv manufacturing method in which the CAR library is used. A chimeric antigen receptor (CAR) library of the present invention includes nucleic acids coding for first CARs. Each of the first CARs includes a first antigen-binding domain, a first transmembrane domain, and a first intracellular signaling domain. The first antigen-binding domain includes a first single-chain antibody (scFv) to be screened for the ability to bind to a target antigen. The first scFv includes a first heavy-chain variable region and a first light-chain variable region. The first heavy-chain variable region and the first light-chain variable region meet a predetermined condition.

A supramolecular histochemical system for staining, the system comprising chaotropic ions and a chaotropic ion complexing agent that accepts chaotropic ions as a molecular subject as a molecular guest. The chaotropic ions facilitate diffusion of probes (e.g., antibodies) into and within the tissue sample, followed by binding or dilution of the guest to the subject to facilitate binding of the antibodies to the target antigen and immunostaining or generation of histochemical signals. Alternatively, the micromolecular fluorescent probe can be used as a molecular guest to be compounded with the supramolecular subject to promote deep penetration of the supramolecular subject. A method for performing histology employs a supramolecular system with deep homogeneous histochemistry. The method is relatively fast, scalable, automated and cost effective.

The present application relates to antigen binding molecules comprising a pair of biparatomotic target binding domains, a pair of cytokine receptor binding domains and an Fc domain wherein the target binding domains concurrently bind to a target antigen and the cytokine receptor binding domains bind to a subunit of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor binding domain in the presence of the target antigen allows for selective activation of cytokine receptors and efficient mimicking of cytokine activity in a targeted manner.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting porcine epidemic diarrhea virus NP protein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 1E11 and 5C8 and can efficiently and specifically recognize porcine epidemic diarrhea virus NP protein, amino acid sequences of complementary determining regions of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting the porcine epidemic diarrhea virus NP protein. The risk of non-specific binding and cross reaction is reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography and the like, and provides a stable and reliable biological recognition tool for rapid and accurate detection of the porcine epidemic diarrhea virus.

The invention relates to the field of immunity, in particular to a T cell receptor and application thereof in detecting, diagnosing, preventing, relieving or treating KRAS G12V mutation positive diseases and / or symptoms. The present invention provides an affinity enhanced TCR or a fragment thereof, the CDR3 [alpha] of the affinity enhanced TCR comprising an amino acid substitution at the V106 and / or I117 position relative to the CDR3 [alpha] of the parent TCR. The TCR provided by the invention has high-affinity target antigen peptide binding ability, can significantly improve the target cell recognition ability, can mediate the specific killing effect of effector cells on antigen-positive target cells, and does not have allogeneic reaction on different types of HLA (human leukocyte antigen). The KRAS G12V cell line can be used for treating various KRAS G12V positive cancers, provides an important tool for cell therapy, and shows high technical value and clinical application potential.

The invention belongs to the technical field of antibody preparation, and particularly relates to a monoclonal antibody aiming at human KRT19 and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and accurately target KRT19 in cytoplasm, has good affinity in combination with KRT19, has strong anti-interference ability, effectively ensures that a detection signal is from a target antigen, has a high conformity degree between a detection result and an actual situation, and has good application prospects. A powerful tool is provided for high-sensitivity and high-precision detection of the KRT19 in tissues and / or cells, deep research on functions and regulation mechanisms of the KRT19 in cytoskeleton, epithelial tissue and tumor biology is facilitated, and the kit has important application prospects.

Nanoparticles for engineering cells to express target antigens and methods of treating / preventing cancer or solid tumors using the same.

The invention provides a kit for detecting an AChR antibody based on a CBA method. The kit comprises skeletal muscle primary cells of fetal mice and skeletal muscle primary cells of adult mice. The skeletal muscle primary cells of fetal rats and adult rats obtained through primary cell isolation culture can naturally express fetal and adult AChR target antigens respectively, and compared with a traditional cell transfection technology, the skeletal muscle primary cells of fetal rats and adult rats obtained through the method have natural AChR protein expression, and can be used for preparing the skeletal muscle primary cells of fetal rats and adult rats. The problems of high cytotoxicity and low detection sensitivity caused by transient expression of five subunits and polymeric protein in traditional cell transfection are successfully avoided, and the detection sensitivity of the AChR antibody is effectively improved.

The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.